M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2- 4N0M0 carcinoma of the bladder

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 4, 1996, Pages 344-348

  Bellmunt, J ^a,b   Ribas, A ^a   Albanell, J ^a   Bermejo, B ^a   Vera, R ^a   De Torres, J A ^a   Morote, J ^a   Lopez Pacios, M A ^a   Banus, J M ^a   Rovirosa, A ^a   Carulla, J ^a   Sole, L A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Medical Oncology Section   (Spain)

Author keywords

Bladder cancer; Carboplatin; Neoadjuvant chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; METHOTREXATE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA;

ACTUARIAL ANALYSIS; ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REMISSION INDUCTION; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 8944234855     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199608000-00004     Document Type: Article

References (35)

1. Sternberg CN, Yagoda A, Scher HI. M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139:461-9.
2. Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group Study. J Clin Oncol 1985;3:1463-70.
3. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
4. Logothetis CJ, Dexeus F, Sella A, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced urothelial tumors. J Clin Oncol 1990;8:1050-5.
5. Canetta R, Rozencweig M, Carter SR. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985;12:125-36.
6. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III (suboptimal) and IV ovarian cancer. J Clin Oncol 1992;10:706-17.
7. Oliver RTD, Knok HK, Highman WJ, et al. Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. Br J Urol 1985;58:31-5.
8. Marcuello E, Izquierdo MA, Germa JR, et al. Carboplatin for advanced bladder cancer. Eur J Cancer 1990;26:849-50.
9. Raabe NK, Fossa SD, Paro G. Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. Br J Urol 1989;64:604-7.
10. Bellmunt J, Albanell J, Gallego O, el al. Carboplatin, methotrexate, and vinblastine (M-CAVI) in bladder cancer patients ineligible to cisplatin-based chemotherapy. Cancer 1992;70:1974-9.
11. Harland FJ, Fenwick E. Carboplatin and methotrexate in advanced bladder cancer [Abstract]. Proc Am Soc Clin Oncol 1989;8:571.
12. Waxman J, Abel P, James N, et al. New combination chemotherapy programme for bladder cancer. Br J Urol 1989;63:68-71.
13. Boccardo F, Pace M, Guarneri D, Canobbio L, Curotto A, Martorana G. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. Cancer 1994;73:1932-6.
14. Alexopoulos CG, Vaslamatzis M, Papachristodoulou A, et al. Combination chemotherapy based on cisplatin or carboplatin in advanced urothelial cancer [Abstract]. Proceedings of XV ESMO. Ann Oncol 1990;1(Suppl):77.
15. Dogliotti L, Bertetto O, Clerico M, et al. Carboplatin (CBDCA) and methotrexate (MTX) combination in the treatment of advanced urothelial cancer [Abstract]. Proc Am Soc Clin Oncol 1993;12:239.
16. Solá C, Mallafré J, Mendoza L, et al. Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell carcinoma. Ann Oncol 1993;4:313-6.
17. Arena MG, Sternberg CN, Zeuli M, et al. Carboplatin and 5-fluorouracil in poor performance status patients with advanced urothelial cancer. Ann Oncol 1993;4:241-4.
18. Klocker J, Pont J, Schumer J et al. Carboplatin, methotrexate and vinblastin (Carbo-MV) for advanced urothelial cancer. Am J Clin Oncol 1991;14:328-30.
19. Small EJ, Ernest ML, Carroll P, et al. A phase II study of carboplatinum (CBDCA), methotrexate (M) and vinblastine (V) (CAMV) for advanced transitional cell carcinoma (TCC) [Abstract]. Proc Am Soc Clin Oncol 1993;12:240.
20. Urinary bladder. In: Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe U, Sobin LH, Wagner G, eds. TNM atlas. Illustrated guide to the TNM/pTNM-classification of malignant tumours, 3rd ed. Berlin: Springer-Verlag, 1989:245-50.
21. Calvert AH, Newell DR, Grumbell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
22. Vagoda A. Progress in treatment of advanced urothelial tract cancer tumors. J Clin Oncol 1985;3:1448-50.
23. Zar JH. Biostatistical analysis, 2nd ed. Englewood Cliffs, NJ: Prentice Hall, 1984:390-95.
24. Fisher RA. Statistical methods for research workers, 14th ed. New York: Hafner Press, 1970:76-96.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
27. Mechl Z, Sopkova B, Nekulova M, et al. Phase II trial of carboplatin in advanced bladder cancer [Abstract]. Proc Eur Conf Clin Oncol-4 1987;63:237.
28. Germa JR, Marcuello E, Sanchez Parra M, et al. A phase II trial of carboplatin in advanced or metastatic transitional carcinoma of the bladder [Abstract]. Proc Eur Conf Clin Oncol-4 1987;63:240.
29. Ogawa M, Inuyama Y, Kato T, et al. Phase II study of carboplatin [Abstract]. Proc Am Soc Clin Oncol 1987;6:20.
30. Lorusso V, Berardi F, Brandi M, et al. M-VECA (methotrexate, vinblastin, epidoxorubicin and carboplatin) in the treatment of advanced urothelial carcinoma. Tumori 1993;79:191-4.
31. Schultz PK, Herr HW, Zhang Z, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994;12:1394-401.
32. Seidman AD, Scher HI, Gabrilove JL, et al. Dose intensification of MV AC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993;11:408-14.
33. Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicm and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993;150:1131-4.
34. Loehrer PJ, Elson P, Dreicer R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1994;121:483-8.
35. Bellmunt J, Albanell J, Vicente P, Gallego OS, Carulla J, Sole Calvo LA. A prospective randomized trial comparing MVAC with MCAVI (methotrexate, carboplatin, vinblastine) in patients with bladder cancer [Abstract]. Proc Am Soc Clin Oncol 1993;12:237.